The GioTag study demonstrated that sequential Gilotrif (afatinib) and osimertinib contributed to a median overall survival of nearly four years (47.6 months) among U.S. patients (129) with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer and the common resistance mutation, T790M.
Real-world data analysis confirms sequential Gilotrif followed by osimertinib provided a median OS of nearly four years in NSCLC indication
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.
Two decades after uncovering the role of EGFR mutations in lung cancer, scientists are still grappling with lingering research questions.
Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.
Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.
